Zhenghong Liu

Aug 19, 2024 | biorxiv.org | Suowen Xu |Zhenghong Liu |Tian Tian |Wenqi Zhao

AbstractObesity is a debilitating disease with increasing worldwide prevalence. Despite its high prevalence, specific pharmacologic intervention for obesity is challenging. Here, we report that halofuginone, an FDA-approved anti-scleroderma and anti-protozoal drug, is a promising anti-obesity agent in rodent models.

Nov 28, 2023 | onlinelibrary.wiley.com | Zhenghong Liu |Li Sun |Bin Zheng |Heng Wang

1 INTRODUCTION Bladder cancer (BCa) is the ninth most common malignancy worldwide.1 Every year approximately 573,000 new cases are diagnosed, and more than 213,000 patients die of BCa globally.2 The BCa incidence increases with age, and it is strongly associated with male gender, with men four times more frequently affected than women.3 The main risk factors for BC are tobacco smoking and occupational exposure.4 In terms of pathological types, urothelial carcinoma is dominant in North America...